These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38943156)

  • 1. Identification of T2W hypointense ring as a novel noninvasive indicator for glioma grade and IDH genotype.
    Lu Y; Du N; Fang X; Shu W; Liu W; Xu X; Ye Y; Xiao L; Mao R; Li K; Lin G; Li S
    Cancer Imaging; 2024 Jun; 24(1):80. PubMed ID: 38943156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
    Guo D; Jiang B
    Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Histogram Features on Arterial Spin Labeling Perfusion Magnetic Resonance Imaging in Identifying Isocitrate Dehydrogenase Genotypes and Glioma Malignancies.
    Su C; Peng C; Sun Y; Damen FC; Jiang R; Xie C; Cai K
    Turk Neurosurg; 2024; 34(4):578-587. PubMed ID: 38874235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
    Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
    J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.
    Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F
    Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
    Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
    Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
    Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
    J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.